期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌EGFR-TKIs耐药机制的研究进展 被引量：6

Research progress of the mechanisms on the drug-resistance of EGFR-TKIs in non-small cell lung cancer
下载PDF
导出
摘要 近年来,随着医学分子生物学的飞速发展,分子靶向治疗理念的提出使肿瘤治疗进入一个新阶段。在对非小细胞肺癌(NSCLC)的分子学研究中,表皮生长因子受体(EGFR)突变成为目前研究最热门的分子靶点,针对这一靶点的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)如吉非替尼、厄洛替尼等,已经广泛应用于临床治疗。然而,有一部分患者对EGFR-TKIs的治疗并不敏感或对其产生耐药性,影响了EGFR-TKIs的临床疗效。本文就EGFR-TKIs的耐药机制以及解除耐药的相应策略进行综述。 In recent years, medical molecular biology has being rapidly developed and a new era of antitumor treatment is coming with the novel concept for molecular-targeted strategies. Epidemal growth factor receptor tyrosine kinase inhibitors （EGFR- TKIs）, such as gefitinib and erlotinib, have being widely used in clinic. However, the efficiency is limited because of the drug resistance or poor sensitivity in some populations with non-small cell lung cancer（NSCLC） during therapy. The review briefly summarizes the pro- gress on mechanisms of EGFR-TKIs resistance and strategies currently being employed to overcome resistance.
作者 王彩霞 周晓军
机构地区 南京大学医学院临床学院 南京军区南京总医院临床病理中心
出处 《临床肿瘤学杂志》 CAS 2013年第3期279-284,共6页 Chinese Clinical Oncology
关键词 非小细胞肺癌 表皮生长因子受体 酪氨酸激酶抑制剂 耐药 Non-small cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitor Drug resistance
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Inukai M,Toyooka S,Ito S,et al. Presence of epidermal growthfactor receptor gene T790M mutation as a minor clone in non-small cell lung cancer [ J]. Cancer Res, 2006,66(16) :7854-7858.
  • 2Uramoto H, Shimokawa H, Hanagiri T, et al. Expression of se-lected gene for acquired drug resistance to EGFR-TKI in lung ad-enocarcinoma[ J]. Lung Cancer, 2011,73(3) :361 -365.
  • 3Oxnard GR, Janjigian YY, Arcila ME, et al. Maintained sensi-tivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lungcancer recurring after adjuvant erlotinib or gefitinib [ J ]. ClinCancer Res, 2011, 17(19):6322 -6328.
  • 4Brugger W, Thomas M. EGFR-TKI resistant non-small cell lungcancer( NSCLC) : New developments and implications for futuretreatment[ J]. Lung Cancer, 2012,77( 1) :2 - 8.
  • 5Wang M, Zhao J, Zhang LM, et al. Combined erlotinib andcetuximab overcome the acquired resistance to epidermal growthfactor receptors tyrosine kinase inhibitor in non-small-cell lungcancer[ J ]. J Cancer Res Clin Oncol,2012,138(12): 2069-2077.
  • 6Oxnard GR. Arcila ME,Chmielecki J,et al. New strategies in o-vercoming acquired resistance to epidermal growth factor receptortyrosine kinase inhibitors in lung cancer [ J]. Clin Cancer Res,2011, 17(17) :5530 -5537.
  • 7Chen G, Kronenberger P, Teugels E, et al. Targeting the epider-mal growth factor receptor in non-small cell lung cancer cells ; theeffect of combining RNA interference with tyrosine kinase inhibi-tors or cetuximab[ J]. BMC Med, 2012, 10:28.
  • 8Zhang Z,Lee JC,Lin L,et al. Activation of the AXL kinase cau-ses resistance to EGFR-targeted therapy in lung cancer [ J ]. NatGenet, 2012, 44(8) : 852 -860.
  • 9Postel-Yinay S,Ashworth A. AXL and acquired resistance to EG-FR inhibitorsf J]. Nat Genet, 2012,27 ,44(8) : 835 - 836.
  • 10Shaw AT, Yeap BY, Mino-kenudson M, et al. Clinical featuresand outcome of patientes with non-small-cell lung cancer who har-bor EML4-ALK[J]. J Clin Oncol, 2009, 27(26) :4247 -4253.

同被引文献43

  • 1吕丽珊,王金全,邵红伟,黄树林.TCRVβ7.1基因修饰的T细胞对肝癌细胞体外杀伤及体内靶向识别作用的研究[J].中国医药生物技术,2007,2(6):416-421. 被引量：5
  • 2赵俊卿,李云峰,杨之斌.肿瘤细胞发生细胞上皮-间质转变机制的研究[J].肿瘤,2010,30(10):890-893. 被引量：27
  • 3Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,36(1):947-957.
  • 4Douillard JY,Shepherd FA,Hirsh V,et al.Molecular predictors of outcome with gefitinib and docetaxel in previously treated non small cell lung cancer:date from the randomized phase III INTEST trial[J].J Clin Oncol,2010,28(5):744-752.
  • 5Cappuzzo F,Ciuleanu T,Stelmakh L,et al.Erlotinib as maintenance treatment in advanced non small cell lung cancer:a multicentre,randomised,placebo controlled phase 3study[J].Lancet Oncol,2010,11(6):521-529.
  • 6Jackman D,Pao W,Riely GJ,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].J Clin Oncol,2010,28(2):357-360.
  • 7William P,Nicolas P.New driver mutations in non small cell lung cancer[J].Lancet Oncol,2011,12(2):175-180.
  • 8Han B,Zhou X,Zhang RX,et al.Mutations of the epidermal growth factor receptor gene in NSCLC patients[J].Oncol Lett,2011,2(6):1233-1237.
  • 9Cappuzzo F,Marchetti A,Skokan M,et al.Increased MET gene copy number negatively affects survival of surgically resected non small cell lung cancer patients[J].J Clin Oncol,2009,27(10):1667-1674.
  • 10Uramoto H,Iwata T,Onitsuka T,et al.Epithelial mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma[J].Anticancer Res,2010,30(7):2513-2517.

引证文献6

二级引证文献44

临床肿瘤学杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部